Peptide Initiative

Peptides · Peptide comparison

Magainin-2 vs Thymosin Alpha-1

Amphipathic 23-amino-acid antimicrobial peptide from Xenopus laevis skin — the founding member of the magainin family discovered by Michael Zasloff at NIH in 1987, operating through the toroidal pore membrane disruption model with broad-spectrum activity against Gram-positive and Gram-negative bacteria, whose synthetic derivative Pexiganan (MSI-78) advanced to Phase III clinical trials for diabetic foot ulcers

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeMagainin-21–1 %Thymosin Alpha-11.6–1.6 mg
FrequencyMagainin-2Multiple times dailyThymosin Alpha-1Twice weekly
AdministrationMagainin-2Topical application (primary clinical route)Thymosin Alpha-1Subcutaneous injection
Cycle lengthMagainin-24-6 weeksThymosin Alpha-18-12 weeks
Onset speedMagainin-2Rapid (hours to days)Thymosin Alpha-1Moderate (1-2 weeks)
Evidence levelMagainin-2Moderate human trials (Phase 1-2)Thymosin Alpha-1Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Fighting Infections

Magainin-294%
Thymosin Alpha-1No recorded rating

Resistance Prevention

Magainin-291%
Thymosin Alpha-1No recorded rating

Wound Healing

Magainin-282%
Thymosin Alpha-1No recorded rating

Immune Activation

Magainin-2No recorded rating
Thymosin Alpha-195%

Infection Fighting

Magainin-2No recorded rating
Thymosin Alpha-192%

Immune Balance

Magainin-2No recorded rating
Thymosin Alpha-188%

Technical data

Compound specifications

Magainin-2

Molecular formula
C114H180N30O29S
Molecular weight
2,466.9 g/mol (magainin-2); Pexiganan (MSI-78): ~2,500 Da
Half-life
Plasma half-life: minutes (rapid proteolytic degradation by serum proteases); local tissue persistence in wound environment: hours at therapeutic concentrations
Bioavailability
Topical bioavailability: local tissue concentrations achieve bactericidal levels with 1-2% cream formulation; systemic bioavailability minimal — rapidly degraded by tissue proteases if absorbed; poor oral bioavailability
CAS number
108433-95-0

Thymosin Alpha-1

Molecular formula
C129H215N33O55
Molecular weight
3108.32 g/mol
Half-life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS number
62304-98-7

Protocols

Dosing compared

Magainin-2

Topical

  • 1% cream (pexiganan, a magainin-2 analog)Twice daily · Up to 28 daysPexiganan (MSI-78), a synthetic magainin-2 analog, was tested as a 1% topical cream in Phase 3 diabetic foot-ulcer trials and matched oral ofloxacin for clinical improvement (~85-90%) [6]. Native magainin-2 itself has no approved human dosing; figures reflect its clinical-stage analog.

Thymosin Alpha-1

Subcutaneous injection

  • 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
  • 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].

Applications

Best suited for

Magainin-2

Research into topical antimicrobial peptides for diabetic foot ulcer management
Magainin-2 is particularly well-suited for individuals focused on research into topical antimicrobial peptides for diabetic foot ulcer management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Understanding the toroidal pore model of antimicrobial peptide membrane disruption
Magainin-2 is particularly well-suited for individuals focused on understanding the toroidal pore model of antimicrobial peptide membrane disruption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of resistance-proof antimicrobial agents targeting membrane architecture
Magainin-2 is particularly well-suited for individuals focused on development of resistance-proof antimicrobial agents targeting membrane architecture. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Investigation of selective anticancer activity mediated by membrane phospholipid asymmetry
Magainin-2 is particularly well-suited for individuals focused on investigation of selective anticancer activity mediated by membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Alpha-1

Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety profile

Side effects

Magainin-2

Common

  • Application site burning/stinging
  • Local erythema
  • Mild pruritus
  • Increased wound exudate

Uncommon

  • Contact sensitization

Serious

  • No serious systemic adverse effects documented

Thymosin Alpha-1

Common

  • Injection site reactions

Uncommon

  • Mild fatigue
  • Flu-like symptoms
  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research status

Safety & evidence

Magainin-2

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Magainin-2 demonstrates favorable safety in topical antimicrobial wound care studies [2] with minimal systemic absorption through intact skin. Local tissue irritation minimal at therapeutic concentrations (0.1-1% w/w); hemolytic activity negligible at concentrations <10 μM. No serious adverse events in Phase II wound healing trials. Peptide stability dependent on formulation pH; activity preserved at physiologic pH. Resistance development slower than traditional antibiotics.

Contraindications

  • Known hypersensitivity to magainin peptides or amphibian-derived proteins
  • Pregnancy and breastfeeding — insufficient safety data for magainin-derived therapeutics
  • Deep tissue infections requiring systemic antimicrobial therapy — topical magainin has limited tissue penetration depth
  • Severe peripheral vascular disease with non-viable tissue — antimicrobial peptides require viable tissue interface for effective action

Thymosin Alpha-1

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
Safety overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • Organ transplant recipients on immunosuppressants
  • Active autoimmune disease flares
  • Known allergy to thymosin peptides
  • Pregnancy or breastfeeding
  • Children under 18 without medical supervision

Decision guide

Which is right for you?

Magainin-2

Choose Magainin-2 if…

  • Research into topical antimicrobial peptides for diabetic foot ulcer management
  • Understanding the toroidal pore model of antimicrobial peptide membrane disruption
  • Development of resistance-proof antimicrobial agents targeting membrane architecture
  • Investigation of selective anticancer activity mediated by membrane phospholipid asymmetry

Thymosin Alpha-1

Choose Thymosin Alpha-1 if…

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support